Enzymatic activation of a matrix metalloproteinase inhibitor
Authors:
Open Access
- 18 January 2010
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 46 (8) , 1241-1243
Abstract
Matrix metalloproteinase inhibitors (MMPi) possessing a glucose protecting group on the zinc-binding group (ZBG) show a dramatic increase in inhibitory activity upon cleavage by β-glucosidase.Keywords
This publication has 38 references indexed in Scilit:
- MMPs as therapeutic targets—Still a viable option?Seminars in Cell & Developmental Biology, 2008
- Painting the Target Around the Arrow: Two-Step Prodrug Therapies from a Carbohydrate Chemists PerspectiveCurrent Drug Delivery, 2007
- Study on glycosylated prodrugs of toxoflavins for antibody-directed enzyme tumor therapyCarbohydrate Research, 2007
- Synthesis, Characterization, and Metal Coordinating Ability of Multifunctional Carbohydrate-Containing Compounds for Alzheimer's TherapyJournal of the American Chemical Society, 2007
- Combating Alzheimer's Disease With Multifunctional Molecules Designed for Metal PassivationAngewandte Chemie International Edition, 2007
- Tumor-activated Prodrugs—A New Approach to Cancer TherapyCancer Investigation, 2004
- Review: Highly Selective Compounds for the Antibody-Directed Enzyme Prodrug Therapy of CancerAustralian Journal of Chemistry, 2003
- Broad‐spectrum matrix metalloproteinase inhibitor marimastat–induced musculoskeletal side effects in ratsArthritis & Rheumatism, 2003
- Strategies for MMP inhibition in cancer: innovations for the post-trial eraNature Reviews Cancer, 2002
- Matrix Metalloproteinase Inhibitors and Cancer—Trials and TribulationsScience, 2002